Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Non-Hodgkin's lymphomas of the testis comprise 25-50% of testicular tumors in men over 50 years of age. Using the Rappaport histologic terminology, most testicular lymphomas are of the diffuse histiocytic type. Concomitant involvement of Waldeyer's ring or of paranasal sinuses frequently occurs. Eight patients with primary non-Hodgkin's lymphoma of the testis and 2 patients with a lymphoma which arose in the paranasal sinuses and later involved the testis are reported. The median age of the 10 patients was 57 years. 5 of 8 patients with primary testicular lymphoma were in clinical stage IE. 8 of the 10 patients had diffuse histiocytic lymphoma. Using the Kiel histologic terminology, 4 of these 8 patients had diffuse centroblastic lymphoma and 4 had immunoblastic sarcoma. 5 of the 8 patients with primary testicular lymphoma had complete remission after orchiectomy followed by radio- and/or chemotherapy. The median survival of the 8 patients with primary testicular lymphoma was 30 months. The median survival of patients with complete remission was 44 months and in patients without remission 12 months. Careful staging of patients with testicular lymphoma is of decisive therapeutic and prognostic significance.
 ...
PMID:[Non-Hodgkin lymphoma of the testis]. 668 4

Fifty-three non-Hodgkin's lymphoma patients staged I, IE, II, and IIE after laparotomy, received involved field radiotherapy with or without adjunctive chemotherapy. These cases have been analyzed for survival, disease-free survival, sites of relapse, and subsequent management. For nodular lymphoma patients, the five-year survival figure was 87%. While this represents only modest improvement over survival figures for patients staged I and II by lymphangiography, results for patients with upper torso disease were significantly better. Although there was a definite incidence of relapse, early failures common in the lymphangiogram series, were not seen in this study. Of the total group of 14 patients, 4 relapsed after a minimum complete remission period of 20 months. The five-year survival figure for all presentations of stages I and II diffuse histiocytic lymphoma was 85%. This represents a substantial improvement over the corresponding figure of 36% for patients staged clinically after lymphangiography. The improvement in results is credited to more precise staging of patients with peripheral presentations, the use of adjunctive multiple-agent chemotherapy for abdominal and mediastinal presentations, and more effective treatment for relapse. To date, too few patients with peripheral presentations have been treated to determine the value of adjunctive chemotherapy for nodular or diffuse histiocytic patients.
 ...
PMID:Laparotomy staged I and II non-Hodgkin's lymphomas: preliminary results of radiotherapy and adjunctive chemotherapy. 676 82

Lymph node specimens obtained intraoperatively and/or at autopsy from 89 patients with non-Hodgkin's lymphoma were studied immunohistochemically. The peroxidase anti-peroxidase (PAP) technique was used for detecting monoclonal cytoplasmic immunoglobulin (CIg) and for determining the classes and types of immunoglobulins in the tumors. Following rigid criteria, monoclonal CIg was demonstrated in four (16%) of 25 cases of nodular, poorly differentiated lymphocytic lymphoma (NPDL); in three (14%) of 21 cases of diffuse, poorly differentiated lymphocytic lymphoma (DPDL); and in 13 (30%) of 43 cases of diffuse histiocytic lymphoma (DH). Of the four NPDL patients, two had the M kappa, one the A kappa, and one the lambda chain type. Of the three DPDL patients, one had the M kappa, one the G kappa, and one the lambda chain type. Of the 13 DH patients, five had the M kappa, four the A kappa, one the GM kappa, one the A kappa, one the G kappa, and one the kappa chain type. In two DH patients negative for cytoplasmic immunoglobulins, cytoplasmic lysozyme was present, indicating the histiomonocytic nature of the tumor cells. There was no significant difference between the overall survival rates for the DH patients with or without monoclonal CIg. In all three types of lymphoma studied, we encountered many patients (67%) who had tumor cell populations without demonstrable CIg and few patients (11%) with polyclonal CIg. There are several possible reasons why many of the patients were PAP-negative and why some had polyclonal cell populations. The PAP method may be useful in establishing the monoclonal nature of neoplastic lymphoid cell populations.
 ...
PMID:An immunocytochemical study of non-Hodgkin's lymphomas. 679 5

One hundred and twenty-three patients with advanced measureable malignant lymphomas resistant to conventional chemotherapy were entered in a prospectively randomized trial of two teniposide (VM-26)-based combination chemotherapy regimens: V-PLAT (VM-26, cisplatin, and prednisone) and V-HEX (VM-26, hexamethylmelamine, and prednisone). Ninety-seven eligible and evaluable patients received protocol therapy. Sixteen percent of the patients had Hodgkin's disease, and 84% had non-Hodgkin's lymphoma. All patients were ambulatory (Eastern Cooperative Oncology Group Performance status 0, 1, or 2), 70% had stage IV disease, 59% had "B" symptoms, and all had failed either two or three previous chemotherapy regimens. Toxicity was mainly hematologic and significantly greater with V-PLAT. Objective tumor responses were seen in nine of 45 patients (20%) treated with V-PLAT (duration, 4-35 + weeks) and in four of 51 patients (8%) treated with V-HEX (duration, 10-65 + weeks). Among the 12 patients with histologically confirmed histiocytic lymphoma treated with V-PLAT, five (42%) experienced objective tumor responses, including two complete responses. Overall median survival was approximately 6 months, with no difference between treatment regimens. Limited antitumor activity of these combination regimens in patients with advanced malignant lymphomas has been demonstrated. However, the objective response rates were not higher than we have previously seen with either VM-26 (22%) or hexamethylmelamine (27%) given in maximum tolerable doses as single agents.
 ...
PMID:Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas. 681 57

A primary histiocytic lymphoma arising in the esophagus and its resultant spontaneous perforation is reported in a 69-year-old female. To our knowledge esophageal perforation occurring as a complication of a primary non-Hodgkin's lymphoma of the esophagus has not been previously reported.
 ...
PMID:Esophageal perforation. An unusual presentation of esophageal lymphoma. 683

Instances of central nervous system (CNS) lymphomatous involvement occurring amongst 592 cases of non-Hodgkin's lymphoma (NHL) seen between 1967 and 1977 were reviewed. Lymphomatous complications of the CNS were found in 52 patients (9%): 24 with meningeal lymphoma, 20 with epidural compression and 8 with intracerebral lymphoma. Intracerebral lymphoma presented clinically as large parenchymal deposits of tumor unrelated to leptomeningeal disease. Ninety-eight percent (50/52) of all patients had a diffuse histologic subtype and 82% (42/52) had either histiocytic or diffuse, poorly differentiated lymphocytic lymphoma. Bone marrow involvement was an additional determinant of risk and aided in the selection of patients for possible CNS prophylaxis. Either meningeal or intracerebral lymphoma developed in 35% (6/17) of patients with diffuse histiocytic lymphoma and positive bone marrow biopsies. This subgroup was particularly felt to warrant CNS prophylaxis. Further diagnostic and therapeutic management regarding CNS involvement in NHL is discussed.
 ...
PMID:CNS involvement in the non-Hodgkin's lymphomas. 698 99

Levels of serum copper in 34 patients with adult non-Hodgkin's lymphoma at different phases of the disease have been studied. All of the patients were evaluated with complete blood counts, sedimentation rate, gallium scintigraphy, liver and bone marrow biopsies, lymph node biopsy, and laparoscopy. The level of serum copper was significantly elevated in non-responding or relapsing patients (mean 191.06 micrograms/dl), and correlated with the estimated tumor burden. Serum copper levels within normal range were found in patients in complete remission (mean 114.76 micrograms/dl). Age- and sex-matched normal controls also showed serum copper levels within normal range (mean 112.81 micrograms/dl). It is proposed that serial measurements of serum copper level may be of use in: (1) monitoring the remission status of patients with non-Hodgkin's lymphoma, (2) detecting early relapse of non-Hodgkin's lymphoma, and (3) contrary to previous reports by Hrgovcic et al., the level of serum copper seems to be related to the disease activity of histiocytic lymphoma.
 ...
PMID:Serum copper levels in non-Hodgkin's lymphoma. 698 85

Nodular histiocytic lymphoma (NH) is uncommon, and its natural history is not well defined. Of 473 patients with non-Hodgkin's lymphoma, we found 16 (3.4%) with NH. Most patients (13/16) presented with pathologic stage (PS) III or IV disease, including 7 with liver involvement. One patient (PS III) was initially treated with cyclophosphamide alone, and 4 patients received only radiotherapy, and none were long-term survivors. Eleven patients received combination chemotherapy, and 8 achieved complete remission. Only one of these patients relapsed and died at 19 mo; the other 7 continue in complete remission without maintenance therapy with a minimum followup of 4.5 yr. The survival of the entire group of patients with NH is intermediate between that of the other nodular lymphomas and diffuse histiocytic lymphoma. Nine of 16 patients had either a repeat lymph node biopsy during the course of their disease or lymph node examination at autopsy. Lymph node histology in the majority converted to a diffuse, less differentiated subtype of lymphoma. NH has a natural history similar to that of diffuse histiocytic lymphoma and should be approached with the same therapeutic strategy.
 ...
PMID:Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. 699 89

The pretreatment serum lactate dehydrogenase level (LDH) was the single most important prognostic variable in 30 patients with diffuse histiocytic lymphoma treated between January 1973 and January 1977 with a poly-drug chemotherapy program called the cyclophosphamide L2 protocol at the Memorial Sloan-Kettering Cancer Center. A highly significant difference was found between the survival patterns of patients with LDH levels of 500 U or less and those with LDH levels greater than 500 U. (Two-year survival rates were 67% and 13%, respectively.) A similar trend was observed for 25 patients with diffuse, poorly differentiated lymphocytic lymphoma treated with the same protocol, although this difference was not statistically significant. (Corresponding two-year survival rates were 74% and 33%, respectively.) The association of LDH level with survival was evident even after adjustment for other factors of potential prognostic significance. Pretreatment serum LDH determinations may provide a useful means of stratifying patient populations when comparing treatment programs for advanced stage non-Hodgkin's lymphoma.
 ...
PMID:Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. 699 74

Diffuse histiocytic lymphoma (DHL) developed in 14 patients with a different non-Hodgkin's lymphoma and one with chronic lymphocytic leukemia. The median time from the diagnosis of the first malignancy to the appearance of DHL was 47 months (range, 8--112). The most common presentation of histologic conversion was new or recurrent lymphadenopathy. Hypercalcemia was associated with the onset of the DHL in four of 15 patients. Eight patients with DHL after histologic conversion were treated with doxorubicin, vincristine, and prednisone with or without cyclophosphamide, but none achieved complete remission. Two other patients did achieve a complete response with therapy (one with radiotherapy and one with cyclophosphamide, vincristine, procarbazine, and prednisone), but they had brief remissions, and no patient in this study achieved long-term, disease-free survival. This was reflected in the short (12-month) median survival after histologic transformation to DHL. It appears that patients with DHL after histologic conversion have a worse prognosis than those with de novo DHL.
 ...
PMID:Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. 701 24


<< Previous 1 2 3 4 5 6 7 8 9 Next >>